[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2000004892A3 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions Download PDF

Info

Publication number
WO2000004892A3
WO2000004892A3 PCT/US1999/013948 US9913948W WO0004892A3 WO 2000004892 A3 WO2000004892 A3 WO 2000004892A3 US 9913948 W US9913948 W US 9913948W WO 0004892 A3 WO0004892 A3 WO 0004892A3
Authority
WO
WIPO (PCT)
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
PCT/US1999/013948
Other languages
French (fr)
Other versions
WO2000004892A2 (en
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Thomas Michael Andrew Bocan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HR20010055A priority Critical patent/HRP20010055A2/en
Priority to PL99346011A priority patent/PL346011A1/en
Priority to IL14098299A priority patent/IL140982A0/en
Priority to EEP200100046A priority patent/EE200100046A/en
Priority to JP2000560885A priority patent/JP2002521328A/en
Priority to SK50-2001A priority patent/SK502001A3/en
Priority to EP99930483A priority patent/EP1098662A2/en
Priority to APAP/P/2001/002035A priority patent/AP2001002035A0/en
Priority to AU47017/99A priority patent/AU4701799A/en
Application filed by Warner Lambert Co, Thomas Michael Andrew Bocan filed Critical Warner Lambert Co
Priority to KR1020017000930A priority patent/KR20010083134A/en
Priority to EA200100153A priority patent/EA200100153A1/en
Priority to BR9912296-0A priority patent/BR9912296A/en
Priority to CA002335062A priority patent/CA2335062A1/en
Publication of WO2000004892A2 publication Critical patent/WO2000004892A2/en
Publication of WO2000004892A3 publication Critical patent/WO2000004892A3/en
Priority to IS5809A priority patent/IS5809A/en
Priority to BG105162A priority patent/BG105162A/en
Priority to NO20010291A priority patent/NO20010291D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.
PCT/US1999/013948 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions WO2000004892A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU47017/99A AU4701799A (en) 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
IL14098299A IL140982A0 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
KR1020017000930A KR20010083134A (en) 1998-07-21 1999-06-18 Coadministration of ACAT and MMP Inhibitors for the Treatment of Atherosclerotic Lesions
JP2000560885A JP2002521328A (en) 1998-07-21 1999-06-18 Combination administration of ACAT inhibitor and MMP inhibitor for treatment of atherosclerotic lesions
SK50-2001A SK502001A3 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP99930483A EP1098662A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
APAP/P/2001/002035A AP2001002035A0 (en) 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.
HR20010055A HRP20010055A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EEP200100046A EE200100046A (en) 1998-07-21 1999-06-18 Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
PL99346011A PL346011A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EA200100153A EA200100153A1 (en) 1998-07-21 1999-06-18 JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS
BR9912296-0A BR9912296A (en) 1998-07-21 1999-06-18 Co-administration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
CA002335062A CA2335062A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
IS5809A IS5809A (en) 1998-07-21 2001-01-12 Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration
BG105162A BG105162A (en) 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
NO20010291A NO20010291D0 (en) 1998-07-21 2001-01-18 Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic wounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
US60/093,639 1998-07-21

Publications (2)

Publication Number Publication Date
WO2000004892A2 WO2000004892A2 (en) 2000-02-03
WO2000004892A3 true WO2000004892A3 (en) 2000-05-18

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291D0 (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465758B2 (en) 2001-01-11 2013-06-18 Abbott Laboratories Drug delivery from stents

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (en) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Prevention of plaque rupture by ACAT inhibitors
GT200000203A (en) 1999-12-01 2002-05-24 COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND ELONGATION OF NEURONS.
EP1237862A1 (en) * 1999-12-17 2002-09-11 Versicor, Inc. Succinate compounds, compositions and methods of use and preparation
AU8254101A (en) * 2000-09-01 2002-03-22 Sankyo Co Medicinal compositions
DE60321775D1 (en) * 2002-04-03 2008-08-07 Topotarget Uk Ltd CARBOXIC ACID DERIVATIVES CONTAIN A PIPERAZINE COMPOUND AS HDAC INHIBITORS
CA2492035A1 (en) * 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019330A1 (en) * 1993-02-18 1994-09-01 Warner-Lambert Company Heterocyclic-substituted alkyl amide acat inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1997005868A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
WO1997044315A1 (en) * 1996-05-17 1997-11-27 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019330A1 (en) * 1993-02-18 1994-09-01 Warner-Lambert Company Heterocyclic-substituted alkyl amide acat inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1997005868A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
WO1997044315A1 (en) * 1996-05-17 1997-11-27 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465758B2 (en) 2001-01-11 2013-06-18 Abbott Laboratories Drug delivery from stents

Also Published As

Publication number Publication date
AU4701799A (en) 2000-02-14
BG105162A (en) 2001-12-29
WO2000004892A2 (en) 2000-02-03
YU3501A (en) 2005-06-10
ID30030A (en) 2001-11-01
EP1098662A2 (en) 2001-05-16
EA200100153A1 (en) 2001-08-27
AP2001002035A0 (en) 2001-03-31
PL346011A1 (en) 2002-01-14
NO20010291L (en) 2001-01-18
IL140982A0 (en) 2002-02-10
EE200100046A (en) 2002-06-17
KR20010083134A (en) 2001-08-31
CA2335062A1 (en) 2000-02-03
JP2002521328A (en) 2002-07-16
OA11584A (en) 2004-07-20
TR200100205T2 (en) 2001-05-21
SK502001A3 (en) 2002-06-04
BR9912296A (en) 2001-04-17
ZA200100294B (en) 2002-01-10
CN1310629A (en) 2001-08-29
IS5809A (en) 2001-01-12
HUP0102880A3 (en) 2002-11-28
NO20010291D0 (en) 2001-01-18
HUP0102880A2 (en) 2002-06-29
CZ2001126A3 (en) 2002-01-16
HRP20010055A2 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
WO2000004892A3 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
PT1011682E (en) HORMONAL CONTRACEPTIVE
AU2710500A (en) Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
AU7867800A (en) Rapid expansion tampon pledget
WO1999032074A3 (en) Oral care composition
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
AU3364899A (en) Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer
MXPA01005165A (en) Dual mode emergency braking apparatus and method of use thereof.
PL352200A1 (en) Inhibitors of viia agent
EP1101420A4 (en) Spike ensuring stable kick during running and spike shoes
ZA200202322B (en) Conventional brake pipe continuity test.
AU2001260214A1 (en) Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
HU9801075D0 (en) Fixed-dose association of an angiotensinconverting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascular illnesses
EP1102578A4 (en) A new analgesic, anti-inflammatory and wound healing agent
AU1892500A (en) Method of manufacturing brake shoe and device used for the method
WO1999043308A3 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
AU5939898A (en) Agent for the pre-symptomatic detection, prevention and treatment of breast cancer in humans
AU4144099A (en) Use of an agent for the prevention of gum disease
AU2001247560A1 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
GB2358051A8 (en) Brake shoe and internal shoe drum brake
HK1033310A (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
AU7833298A (en) New human carboxypeptidase inhibitor
SE9802198D0 (en) Sanitary napkin
AU2002335346A1 (en) Lymphocytic activation inhibitor and remedial agent for autoimmune disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-35/01

Country of ref document: YU

Ref document number: 99808958.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2335062

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00019/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 47017/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200100030

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: PV2001-126

Country of ref document: CZ

Ref document number: 2001/00294

Country of ref document: ZA

Ref document number: 200100294

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 502001

Country of ref document: SK

Ref document number: 1999930483

Country of ref document: EP

Ref document number: 509358

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1999 105162

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 140982

Country of ref document: IL

Ref document number: 2001/00205

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 560885

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20010055A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 1020017000930

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000780

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200100153

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20010138

Country of ref document: UZ

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999930483

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017000930

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09744185

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-126

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999930483

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017000930

Country of ref document: KR